Dr. Olga Bezzubova

Partner

München + 49.89.20.60.42.200

Connect

Share

Olga Bezzubova ist die Leiterin der Münchner Patentanwaltspraxis und der Europäischen Patenterteilungsgruppe für Biowissenschaften und Chemie. Sie verfügt über umfangreiche Erfahrung in der Erlangung und Verteidigung von Rechten an geistigem Eigentum für Mandanten aus den Bereichen Pharma, Biotechnologie und Diagnostik.

Frau Dr. Bezzubova berät zu allen Aspekten der Patenterteilung und des Einspruchsverfahrens, zu ergänzenden Schutzzertifikaten (SPC), zur Patentgültigkeit und -verletzung.

Sie hat erfolgreich Dutzende europäische Einspruchsverfahren auf Patentinhaber- und Einsprechendenseite für Unternehmen wie BMS/Celgene, Merck, Puma und Akebia Therapeutics in den Bereichen kleine und große Moleküle, einschließlich Antikörper, ADCs (Antikörper-Wirkstoff-Konjugate) und CAR-Ts (chimäre Antigenrezeptor-T-Zellen), geführt. Frau Dr. Bezzubova hat Mandanten insbesondere in den Bereichen der RNA- (Ribonukleinsäure)-Interferenz (RNAi) und der CRISPR/Cas-Geneditierung (Clustered Regularly Interspaced Short Palindromic Repeats) vertreten, war an Nichtigkeits- und Verletzungsverfahren im Zusammenhang mit der Aminosäureproduktion beteiligt und erwirkte SPCs für die erste zugelassene Gentherapie gegen SMA (Spinale Muskelatrophie). Sie verfügt über Erfahrung in der Entwicklung globaler IP-Strategien für etablierte Biotech-Unternehmen und Start-ups sowie in der Verwaltung weltweiter Patentportfolios. Ihr einzigartiger Hintergrund in Physik und Biologie ermöglicht es ihr, Mandanten in Angelegenheiten zu beraten, die verschiedene Aspekte der Zellbiologie, Genomik, Proteomik, Molekularbiologie, Lebensmittelwissenschaft, Biopharmazeutika und Biophysik sowie neue Technologien an der Schnittstelle zwischen biologischen und physikalischen Wissenschaften, betreffen.

Erfahrung

  • BioMarin pursues litigation against Ascendis Pharma A/S in UPCJones Day represents BioMarin Pharmaceutical, Inc. in patent infringement proceedings against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide ("CNP").
  • Atara and leading cancer center develop patent portfolios for antigen-specific T cell therapiesJones Day represents Atara Biotherapeutics, Inc. and a leading cancer center in the development of patent portfolios relating to antigen-specific T cell therapies, including EBVALLO™ (tabelecleucel).
  • BMS secures EPO precedential victory on epitope claimsJones Day successfully represented licensee Bristol Myers Squibb’s wholly owned subsidiary Celgene Corporation in the defense of European patent EP 2812443 directed to CD47 antibodies defined by a conformational epitope, in opposition proceedings at the European Patent Office, triggering the first decision that acknowledges patentability of conformational epitope claiming in Europe.
  • Hookipa successfully defends its tri-segmented arenavirus platform technology patent in EPO opposition proceedingsJones Day successfully defended Hookipa Biotech GmbH in opposition proceedings at the European Patent Office.
  • Akebia successfully challenges European patentJones Day represented Akebia Therapeutics, Inc. in successfully challenging the validity of European Patent No. EP1463823 issued to FibroGen, Inc. in opposition proceedings before the European Patent Office ("EPO").
  • Turnstone Biologics develops patent portfolios for its oncolytic virus clinical candidateJones Day is representing Turnstone Biologics Corp. in the development of patent portfolios covering its oncolytic virus programs.
  • Astellas and Agensys prosecute patent portfolios for novel monoclonal antibody and antibody-drug conjugate immunotherapeutics useful for certain cancer treatmentsJones Day represents Astellas Pharma Inc. and its subsidiary Agensys, Inc. in prosecuting their worldwide patent portfolios related to novel monoclonal antibody and antibody-drug conjugate (ADC) immunotherapeutics for use in the treatment of a variety of cancer indications, including PADCEV®, an ADC approved by the FDA in 2019 for the treatment of metastatic bladder cancer.
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day represented CJ CheilJedang Corporation, a major Korean-based multinational company, in an international patent dispute with a Japanese competitor before the courts in Germany, including the Federal Supreme Court of Germany.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Puma Biotechnology obtains dismissal of opposition against its European patent relating to treatment for gefitinib/erlotinib-resistant cancers and cancers with T790M EGFR mutationAfter nearly 10 years of opposition and appeal proceedings, on behalf of Puma Biotechnology, Inc., Jones Day obtained dismissal of an opposition against a European patent, which broadly covers the use of irreversible inhibitors for the treatment of gefitinib/erlotinib-resistant cancers, as well as cancers with the T790M EGFR mutation.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®).
  • ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technologyJones Day is acting for ToolGen, Inc. in defense of a multi-party opposition filed at the European Patent Office against its patent rights covering application of the revolutionary CRISPR/Cas9 gene editing technology in biotechnology, medicine, and agriculture.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
    •

    December 2025 Commentary

    UPC Aligns With the EPO in Allowing Functional Antibody Claims

    December 10, 2025 Webinars

    Women in IP Speaker Series - Dynamics of Invalidity Challenges in Europe and the U.S

    December 2024 Commentary

    Unified Patent Court: First Ruling on Equivalent Infringement

    November 2024 Commentary

    UPC: Patentees No Longer Locked Out by Pre-Transitional Period National Litigations

    November 2024 Commentary

    The Unified Patent Court: Also an Attractive Jurisdiction for SMEs

    October 2024 Commentary

    A Rollback on Referral to the EBA Regarding Adaptation of Description

    August 2024 Alert

    Epitope Claims Live On at the European Patent Office

    July 2024 Commentary

    EU Parliament Adopts SPC Reform Proposals: Clarifying the Protection Scope for Biologics

    March 2024 Alert

    Finish in Eight Months: The EPO Sets Timeline for New Accelerated Opposition Practice

    March 2024 Alert

    Unified Patent Court Publishes Its First Case Load Statistics
    Weitere Veröffentlichungen

    December 10, 2025 Webinars

    Women in IP Speaker Series - Dynamics of Invalidity Challenges in Europe and the U.S

    • February 7, 2017
      Brexit and the Unitary Patent System, JD Women in IP
    • November 19, 2013
      IP Strategies for Life Science Companies: The New European System, Seminar for France Biotech
    • June 4, 2013
      Divisionals in Europe: Practical Advice
    • March 25, 2013
      Europe's New Unitary Patent and Unified Patent Court: How the introduction of the Unitary Patent and Unified Patent Court will impact your existing patent portfolio

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.